To evaluate the expression of Th1, Th2, and Th17 cytokines in patients with systemic lupus erythematosus (SLE), and verify the association between serum cytokine levels and vitamin D concentration.
Methods
The sample consisted of 172 patients with SLE. 25-Hydroxyvitamin D (25(OH)D) levels were measured by chemiluminescence and 25(OH)D levels <20 ng/mL were considered to reflect vitamin D deficiency. Serum cytokine levels were measured in once-thawed samples, using a Th1/Th2/Th17 CBA (cytometric beads array) kit.
Results
One hundred and sixty-one (93.6%) patients were women and 128 (74.4%) were of European descent. Mean patient age was 40.5 ± 13.8 years, and mean age at diagnosis was 31.5 ± 13.4 years. At the time of study entry, patients had a median (IQR) SLEDAI of 2 (1–4) and SLICC of 0 (0–1). Mean 25(OH)D concentration was 25.4 ± 11.04 ng/mL. Fifty-nine (34.3%) patients had a vitamin D deficiency. No statistically significant associations were identified between cytokine and vitamin D levels. The most significant finding was a positive correlation between INF-α levels and SLEDAI (rs = 0.22, p = 0.04).
Conclusion
Although vitamin D deficiencies are highly prevalent in patients with SLE, vitamin D levels were not significantly associated with patient cytokine profiles. The positive correlation between IFN-α levels and SLEDAI showed in this study corroborates other findings in the literature. The present results did not replicate those of in vitro studies of the effect of vitamin D levels on cytokine profiles. Placebo-controlled intervention trials of the effect of vitamin D on cytokine profiles are still required before any definitive conclusions can be drawn regarding the association between these variables.
UramotoKMMichetCJThumbooJSunkuJO’FallonWMGabrielSE. Trends in the incidence and mortality of systemic lupus erythematosus, 1950–1992. Arthritis Rheum1999; 42: 46–50.
2.
KamenDLTangprichaV. Vitamin D and molecular actions on the immune system: modulation of innate and autoimmunity. J Mol Med2010; 88: 441–450.
3.
NormanAW. Sunlight, season, skin pigmentation, vitamin D, and 25-hydroxyvitamin D: integral components of the vitamin D endocrine system. Am J Clin Nutr1998; 67: 1108–1110.
4.
QiaoSWIversenRRákiMSollidLM. The adaptive immune response in celiac disease. Semin Immunopathol2012; 34: 523–540.
5.
ArnsonYAmitalHShoenfeldY. Vitamin D and autoimmunity: new aetiological and therapeutic considerations. Ann Rheum Dis2007; 66: 1137–1142.
6.
AdoriniLPennaG. Control of autoimmune diseases by the vitamin D endocrine system. Nat Clin Pract Rheumatol2008; 4: 404–412.
7.
MonticieloOATeixeiraTeMChiesJABrenolJCXavierRM. Vitamin D and polymorphisms of VDR gene in patients with systemic lupus erythematosus. Clin Rheumatol2012; 31: 1411–1421.
8.
SouberbielleJCBodyJJLappeJM. Vitamin D and musculoskeletal health, cardiovascular disease, autoimmunity and cancer: recommendations for clinical practice. Autoimmun Rev2010; 9: 709–715.
9.
KamenDLAranowC. The link between vitamin D deficiency and systemic lupus erythematosus. Curr Rheumatol Rep2008; 10: 273–280.
10.
RitterhouseLLCroweSRNiewoldTB. Vitamin D deficiency is associated with an increased autoimmune response in healthy individuals and in patients with systemic lupus erythematosus. Ann Rheum Dis2011; 70: 1569–1574.
11.
ReinerSL. Development in motion: helper T cells at work. Cell2007; 129: 33–36.
12.
AranowC. Vitamin D and the immune system. J Invest Med2011; 59: 881–886.
13.
Alvarez-RodriguezLLopez-HoyosMGarcia-UnzuetaMAmadoJACachoPMMartinez-TaboadaVM. Age and low levels of circulating vitamin D are associated with impaired innate immune function. J Leukoc Biol2012; 91: 829–838.
14.
AlroyITowersTLFreedmanLP. Transcriptional repression of the interleukin-2 gene by vitamin D3: direct inhibition of NFATp/AP-1 complex formation by a nuclear hormone receptor. Mol Cell Biol1995; 15: 5789–5799.
15.
LemireJMAdamsJSKermani-ArabVBakkeACSakaiRJordanSC. 1,25-Dihydroxyvitamin D3 suppresses human T helper/inducer lymphocyte activity in vitro. J Immunol1985; 134: 3032–3035.
16.
DanielCSartoryNAZahnNRadekeHHSteinJM. Immune modulatory treatment of trinitrobenzene sulfonic acid colitis with calcitriol is associated with a change of a T helper (Th) 1/Th17 to a Th2 and regulatory T cell profile. J Pharmacol Exp Ther2008; 324: 23–33.
17.
HochbergMC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum1997; 40: 1725–1725.
18.
BombardierCGladmanDDUrowitzMBCaronDChangCH. Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum1992; 35: 630–640.
19.
GladmanDGinzlerEGoldsmithC. The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus. Arthritis Rheum1996; 39: 363–369.
20.
O’ReganSChesneyRWHamstraAEismanJAO'GormanAMDelucaHF. Reduced serum 1,25-(OH)2 vitamin D3 levels in prednisone-treated adolescents with systemic lupus erythematosus. Acta Paediatr Scand1979; 68: 109–111.
21.
SahebariMNabaviNSalehiM. Correlation between serum 25(OH)D values and lupus disease activity: an original article and a systematic review with meta-analysis focusing on serum VitD confounders. Lupus2014; 23: 1164–1177.
22.
PremaorMOPaludoPManicaD. Hypovitaminosis D and secondary hyperparathyroidism in resident physicians of a general hospital in southern Brazil. J Endocrinol Invest2008; 31: 991–995.
23.
ScalcoRPremaorMOFröehlichPEFurlanettoTW. High prevalence of hypovitaminosis D and secondary hyperparathyroidism in elders living in nonprofit homes in South Brazil. Endocrine2008; 33: 95–100.
24.
BikleD. Nonclassic actions of vitamin D. J Clin Endocrinol Metab2009; 94: 26–34.
25.
Yusupov E, Li-Ng M, Pollack S, Yeh JK, Mikhail M, Aloia JF. Vitamin D and serum cytokines in a randomized clinical trial. Int J Endocrinol 2010; 2010. DOI: 10.1155/2010/305054.
26.
JefferyLEBurkeFMuraM. 1,25-Dihydroxyvitamin D3 and IL-2 combine to inhibit T cell production of inflammatory cytokines and promote development of regulatory T cells expressing CTLA-4 and FoxP3. J Immunol2009; 183: 5458–5467.
27.
DolffSBijlMHuitemaMGLimburgPCKallenbergCGAbdulahadWH. Disturbed Th1, Th2, Th17 and T(reg) balance in patients with systemic lupus erythematosus. Clin Immunol2011; 141: 197–204.
28.
LitLCWongCKLiEKTamLSLamCWLoYM. Elevated gene expression of Th1/Th2 associated transcription factors is correlated with disease activity in patients with systemic lupus erythematosus. J Rheumatol2007; 34: 89–96.
29.
WangYItoSChinoY. Laser microdissection-based analysis of cytokine balance in the kidneys of patients with lupus nephritis. Clin Exp Immunol2010; 159: 1–10.
30.
ElewaEAZakariaOMohamedEIBoghdadiG. The role of interleukins 4, 17 and interferon gamma as biomarkers in patients with systemic lupus erythematosus and their correlation with disease activity. Egypt Rheumatol2014; 36: 21–27.
31.
TerrierBDerianNSchoindreY. Restoration of regulatory and effector T cell balance and B cell homeostasis in systemic lupus erythematosus patients through vitamin D supplementation. Arthritis Res Ther2012; 14: R221–R221.
32.
AmitalHSzekaneczZSzücsG. Serum concentrations of 25-OH vitamin D in patients with systemic lupus erythematosus (SLE) are inversely related to disease activity: is it time to routinely supplement patients with SLE with vitamin D?Ann Rheum Dis2010; 69: 1155–1157.
33.
PetriMBelloKJFangHMagderLS. Vitamin D in systemic lupus erythematosus: modest association with disease activity and the urine protein-to-creatinine ratio. Arthritis Rheum2013; 65: 1865–1871.
34.
BorbaVZVieiraJGKasamatsuTRadominskiSCSatoEILazaretti-CastroM. Vitamin D deficiency in patients with active systemic lupus erythematosus. Osteoporos Int2009; 20: 427–433.
35.
Dall’eraMCCardarelliPMPrestonBTWitteADavisJC. Type I interferon correlates with serological and clinical manifestations of SLE. Ann Rheum Dis2005; 64: 1692–1697.
36.
FengXWuHGrossmanJM. Association of increased interferon-inducible gene expression with disease activity and lupus nephritis in patients with systemic lupus erythematosus. Arthritis Rheum2006; 54: 2951–2962.
37.
ObermoserGPascualV. The interferon-alpha signature of systemic lupus erythematosus. Lupus2010; 19: 1012–1019.
38.
HarigaiMKawamotoMHaraMKubotaTKamataniNMiyasakaN. Excessive production of IFN-gamma in patients with systemic lupus erythematosus and its contribution to induction of B lymphocyte stimulator/B cell-activating factor/TNF ligand superfamily-13B. J Immunol2008; 181: 2211–2219.
QianQLiPWangT. Alteration of Th1/Th2/Th17 cytokine profile and humoral immune responses associated with chromate exposure. Occup Environ Med2013; 70: 697–702.
41.
TucciMLombardiLRichardsHBDammaccoFSilvestrisF. Overexpression of interleukin-12 and T helper 1 predominance in lupus nephritis. Clin Exp Immunol2008; 154: 247–254.
42.
Abou-RayaAAbou-RayaSHelmiiM. The effect of vitamin D supplementation on inflammatory and hemostatic markers and disease activity in patients with systemic lupus erythematosus: a randomized placebo-controlled trial. J Rheumatol2013; 40: 265–272.
